$5.08 EPS Expected for Regeneron Pharmaceuticals, Inc. (REGN) on May, 3

April 16, 2018 - By Mark Williams

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Corporate Logo
Big Money Sentiment is 1.17 in 2017 Q4. It has change of 2017Q3’s as. The ratio is flat due to Regeneron Pharmaceuticals, Inc. positioning: 62 sold and 161 reduced. only 71 funds took holdings and 191 increased holdings. Investors holded 73.70 million in 2017Q3 but now own 69.17 million shares or 6.15% less.
Tekla Mgmt Lc holds 170,516 shs. 4.33 million were accumulated by Wellington Limited Liability Partnership. Avalon Advsrs Limited Liability Corporation reported 0.23% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Sumitomo Life owns 5,150 shs or 0.24% of their US capital. California State Teachers Retirement System reported 0.1% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Macquarie Grp Ltd stated it has 54,124 shs or 0.04% of all its holdings. 7,027 were accumulated by Truenorth Inc. Amp Cap Investors Limited holds 32,773 shs or 0.07% of its capital. Orbimed Advsr Lc invested in 854,600 shs. Wells Fargo And Company Mn has invested 0.02% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Michigan-based State Treasurer State Of Michigan has invested 0.07% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Bnp Paribas Arbitrage Sa invested 0.32% of its capital in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Employees Retirement Of Texas holds 13,000 shs or 0.06% of its capital. 1,670 are held by Chicago Equity Prtn Ltd Liability. The France-based Natixis has invested 0.01% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Regeneron Pharmaceuticals, Inc. registered $1.71 million net activity with 0 insider buys and 3 sales since February 9, 2018.

On May, 3. Investors expect Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to report its quarterly earnings, RTT reports. Analysts forecast 135.19 % diference or $5.08 from the $2.16 EPS from 2017. If earnings per share of $5.08 is published the profit of REGN could hit $546.58 million giving it 15.81 P/E. 13.90 % EPS growth is what analysts predict. $4.46 earnings per share was published for last [previous quarter]. REGN reached $321.18 on during the last trading session after $0.38 change.Regeneron Pharmaceuticals, Inc. has volume of 8,107 shares. Since April 16, 2017 REGN has declined 14.19% and is downtrending. The stock underperformed the S&P 500 by 25.74%.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Ratings Coverage

In total 19 analysts cover Regeneron Pharmaceuticals (NASDAQ:REGN). “Buy” rating has 6, “Sell” are 1, while 12 are “Hold”. 32% are bullish. 31 are the (NASDAQ:REGN)’s analyst reports since October 20, 2017 according to StockzIntelligence Inc. On Thursday, November 9 the stock has “Hold” rating by RBC Capital Markets. On Monday, March 12 Oppenheimer maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with “Hold” rating. On Friday, February 9 the stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has “Outperform” rating given by Leerink Swann. On Monday, November 27 the firm earned “Hold” rating by BMO Capital Markets. On Monday, April 9 the rating was downgraded by Raymond James to “Market Perform”. On Friday, February 9 the firm has “Neutral” rating by BTIG Research given. On Friday, October 20 the stock has “Underweight” rating by Barclays Capital. In Thursday, February 8 report Jefferies maintained it with “Hold” rating and $380.0 target. On Friday, February 9 the stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Equal-Weight” rating by Morgan Stanley. On Friday, February 2 Jefferies maintained the shares of REGN in report with “Hold” rating.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, makes, and commercializes medicines for the treatment of serious medical conditions worldwide.The firm is valued at $34.56 billion. The Company’s products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes.31.06 is the P/E ratio. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: